CytoMed Therapeutics Limited (GDTC) Income Statement
GDTC 2025 at a glance
Fiscal year ended December 31, 2025 · Singapore dollarsGDTC revenue and net income
Where GDTC's revenue goes
2025Each bar shows an amount and its share of revenue. GDTC kept −1,227.1% of revenue as net income.
GDTC profit margins
GDTC growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +359.3% | −4.4% | +48.0% | — |
| Gross profit | −1,792.6% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GDTC income statement in Singapore dollars
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | S$319,201 | S$69,501 | S$509,125 | S$365,604 | S$84,178 | S$44,923 | S$0 |
| Cost of revenue | S$1.2M | S$17,121 | S$3,736 | S$109,042 | S$3,501 | S$4,627 | — |
| Gross profit | −S$886,564 | S$52,380 | S$505,387 | −S$109,042 | S$110,291 | S$54,836 | — |
| Research & development | S$2.2M | S$1.9M | S$1.6M | S$1.5M | S$1.1M | S$1.0M | S$439,796 |
| Sales, general & admin | S$1.8M | S$1.3M | S$490,491 | S$596,506 | S$585,980 | S$154,862 | — |
| Total operating expenses | S$3.6M | S$3.2M | S$2.1M | S$2.2M | S$1.3M | S$1.2M | S$651,880 |
| Operating income | −S$4.5M | −S$3.1M | −S$1.6M | −S$2.3M | −S$1.2M | −S$1.3M | −S$651,880 |
| Interest income | S$123,898 | S$317,670 | S$285,719 | S$2,097 | S$3,369 | S$0 | — |
| Interest expense | S$20,571 | S$20,313 | S$50,522 | S$122,147 | S$118,392 | S$105,512 | — |
| Income before taxes | −S$3.9M | −S$2.6M | −S$4.1M | −S$3.1M | −S$2.1M | −S$1.9M | −S$858,748 |
| Income taxes | — | −S$54,725 | S$653 | S$1,599 | −S$53,427 | S$84,710 | — |
| Net income | −S$3.9M | −S$2.5M | −S$4.1M | −S$3.1M | −S$2.1M | −S$1.9M | −S$858,748 |
| EBITDA | −S$4.1M | −S$1.8M | −S$3.6M | −S$1.9M | −S$1.4M | −S$1.0M | −S$474,603 |
| Gross margin | −277.7% | 75.4% | 99.3% | −29.8% | 131.0% | 122.1% | — |
| Operating margin | −1,416.0% | −4,504.3% | −310.2% | −624.5% | −1,373.6% | −2,955.8% | — |
| Net margin | −1,227.1% | −3,621.1% | −814.0% | −835.7% | −2,463.4% | −4,323.2% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | S$157,673 | S$189,440 | S$167,945 | S$205,081 | S$134,896 | S$134,721 | S$141,701 | S$112,038 | S$112,385 | S$0 | S$111,956 | S$142,249 |
| Cost of revenue | S$534,282 | S$23,661 | S$723,598 | S$31,988 | S$9,349 | S$9,338 | S$14,637 | S$1,103 | S$1,106 | S$38,231 | S$1,187 | S$205,722 |
| Gross profit | −S$376,609 | S$165,779 | −S$555,651 | S$173,092 | S$125,547 | S$125,385 | S$127,065 | S$110,935 | S$111,278 | −S$38,231 | S$110,769 | −S$63,472 |
| Research & development | S$1.1M | S$547,779 | S$1.1M | S$527,514 | S$583,345 | S$582,591 | S$474,620 | S$858,882 | S$488,482 | S$576,611 | S$389,888 | S$406,053 |
| Sales, general & admin | — | S$180,068 | — | S$306,690 | — | S$168,858 | S$171,446 | S$149,876 | S$154,671 | — | S$158,490 | S$684,760 |
| Total operating expenses | S$1.6M | S$727,847 | S$1.8M | S$834,204 | S$777,092 | S$776,087 | S$646,066 | S$641,162 | S$643,153 | S$1.5M | S$548,379 | S$492,507 |
| Operating income | −S$2.0M | −S$562,068 | −S$2.4M | −S$661,112 | −S$651,544 | −S$650,703 | −S$519,000 | −S$530,227 | −S$531,872 | −S$1.5M | −S$437,608 | −S$1.6M |
| Interest expense | S$10,163 | — | S$10,560 | S$5,092 | S$9,938 | S$5,165 | — | S$9,863 | S$10,316 | S$7,796 | — | S$41,285 |
| Income before taxes | −S$1.8M | −S$897,073 | −S$1.7M | −S$875,254 | −S$1.1M | −S$1.1M | −S$727,481 | −S$544,014 | −S$545,704 | −S$1.5M | −S$988,916 | −S$2.2M |
| Income taxes | — | — | — | — | — | — | — | S$569,042 | S$640 | S$484 | S$328 | S$14,676 |
| Net income | −S$1.8M | −S$885,226 | −S$1.7M | −S$868,349 | −S$1.1M | −S$1.1M | −S$724,934 | −S$1.1M | −S$545,630 | −S$1.5M | −S$989,175 | −S$1.1M |
| EBITDA | −S$1.9M | −S$783,527 | −S$2.2M | −S$986,634 | −S$1.0M | −S$1.0M | −S$668,826 | −S$933,456 | −S$743,482 | −S$1.5M | −S$820,181 | −S$1.9M |
| Gross margin | −238.9% | 87.5% | −330.9% | 84.4% | 93.1% | 93.1% | 89.7% | 99.0% | 99.0% | — | 98.9% | −44.6% |
| Operating margin | −1,272.9% | −296.7% | −1,403.1% | −322.4% | −483.0% | −483.0% | −366.3% | −473.3% | −473.3% | — | −390.9% | −1,107.5% |
| Net margin | −1,125.6% | −467.3% | −1,030.7% | −423.4% | −834.7% | −834.7% | −511.6% | −977.4% | −485.5% | — | −883.5% | −759.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in Singapore dollars as reported in GDTC's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GDTC financial results
In fiscal year 2025 (ended December 31, 2025), CytoMed Therapeutics reported revenue of S$0.3 million, up 359.3% from the year before. It had a net loss of S$3.9 million, a net profit margin of −1,227.1%. Over five years revenue grew at an average rate of 48.0% a year. Figures are in Singapore dollars, the currency of its financial statements.
See the GDTC stock overview for the latest quote and news, or the GDTC chart for price history and technical indicators.
GDTC income statement FAQ
What is CytoMed Therapeutics's annual revenue?
CytoMed Therapeutics reported total revenue of S$0.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 359.3% from S$0.1 million the previous year.
Is CytoMed Therapeutics profitable?
No. CytoMed Therapeutics reported a net loss of S$3.9 million in fiscal 2025, a net profit margin of −1,227.1%; its operating margin was −1,416.0%.
What is CytoMed Therapeutics's gross margin?
CytoMed Therapeutics's gross margin was −277.7% in fiscal 2025: for every $100 of revenue, CytoMed Therapeutics kept $-278 after the direct cost of its products and services.
How much does CytoMed Therapeutics spend on research and development?
CytoMed Therapeutics spent S$2.2 million on research and development in fiscal 2025, 683.6% of revenue.
How fast is CytoMed Therapeutics growing?
Revenue grew 48.0% a year on average over the last five fiscal years, from S$0.0 million to S$0.3 million.
When does CytoMed Therapeutics's fiscal year end?
CytoMed Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.